On May 11, 2026, Abivax S.A. held its annual general meeting where shareholders approved financial statements with a participation rate of 86.06%, including nearly unanimous support for the financial results from 2025 (99.99% approval). Key decisions included renewing directors' terms and authorizing share capital increases.